Literature DB >> 16546169

Rat model of Parkinson's disease: chronic central delivery of 1-methyl-4-phenylpyridinium (MPP+).

U Yazdani1, D C German, C-L Liang, L Manzino, P K Sonsalla, G D Zeevalk.   

Abstract

Mitochondrial dysfunction is observed in sporadic Parkinson's disease (PD) and may contribute to progressive neurodegeneration. While acute models of mitochondrial dysfunction have been used for many years to investigate PD, chronic models may better replicate the cellular disturbances caused by long-standing mitochondrial derangements and may represent a better model for neurotherapeutic testing. This study sought to develop a chronic model of PD that has the advantages of continuous low level toxin delivery, low mortality, unilateral damage to minimize aphagia and adipsia as well as minimal animal handling to reduce stress-related confounds. Infusion by osmotic minipump of the complex I toxin, 1-methyl-4-phenylpyridinium (MPP+), for 28 days into the left cerebral ventricle in rats caused a selective ipsilateral loss of nigral tyrosine hydroxylase immunoreactive somata (35% loss). In animals that were sacrificed 14 days after the chronic MPP+ administration, there was an even greater loss of nigral tyrosine hydroxylase cells (65% loss). Lewy-body-like structures that stained positive for ubiquitin and alpha-synuclein were found in striatal neurons near the infusion site but were not observed in nigral neurons. At the electron microscope level, however, swollen and abnormal mitochondria were observed in the nigral dopamine neurons, which may represent the early formation of an inclusion body. There were no animal deaths with the chronic treatment regimen that was utilized, and the magnitude of nigrostriatal neuronal loss was relatively consistent among the animals. This model of progressive neurodegeneration of nigrostriatal dopamine neurons may be useful for studying neuroprotective therapeutic agents for PD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16546169     DOI: 10.1016/j.expneurol.2006.02.002

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  22 in total

1.  Delayed caffeine treatment prevents nigral dopamine neuron loss in a progressive rat model of Parkinson's disease.

Authors:  Patricia K Sonsalla; Lai-Yoong Wong; Suzan L Harris; Jason R Richardson; Ida Khobahy; Wenhao Li; Bharathi S Gadad; Dwight C German
Journal:  Exp Neurol       Date:  2012-01-28       Impact factor: 5.330

2.  Pesticide exposure exacerbates alpha-synucleinopathy in an A53T transgenic mouse model.

Authors:  Erin H Norris; Kunihiro Uryu; Susan Leight; Benoit I Giasson; John Q Trojanowski; Virginia M-Y Lee
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

3.  Orthotopic transplantation of immortalized mesencephalic progenitors (CSM14.1 cells) into the substantia nigra of hemiparkinsonian rats induces neuronal differentiation and motoric improvement.

Authors:  Stefan Jean-Pierre Haas; Stanislav Petrov; Golo Kronenberg; Oliver Schmitt; Andreas Wree
Journal:  J Anat       Date:  2007-11-23       Impact factor: 2.610

Review 4.  Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention.

Authors:  Malú G Tansey; Melissa K McCoy; Tamy C Frank-Cannon
Journal:  Exp Neurol       Date:  2007-07-17       Impact factor: 5.330

Review 5.  Chronic intraventricular administration of 1-methyl-4-phenylpyridinium as a progressive model of Parkinson's disease.

Authors:  Patricia K Sonsalla; Gail D Zeevalk; Dwight C German
Journal:  Parkinsonism Relat Disord       Date:  2008-06-25       Impact factor: 4.891

Review 6.  Modeling PD pathogenesis in mice: advantages of a chronic MPTP protocol.

Authors:  Gloria E Meredith; Susan Totterdell; Judith A Potashkin; D James Surmeier
Journal:  Parkinsonism Relat Disord       Date:  2008-06-27       Impact factor: 4.891

7.  A selective role for ARMS/Kidins220 scaffold protein in spatial memory and trophic support of entorhinal and frontal cortical neurons.

Authors:  Aine M Duffy; Michael J Schaner; Synphen H Wu; Agnieszka Staniszewski; Asok Kumar; Juan Carlos Arévalo; Ottavio Arancio; Moses V Chao; Helen E Scharfman
Journal:  Exp Neurol       Date:  2011-03-16       Impact factor: 5.330

Review 8.  MPTP mouse models of Parkinson's disease: an update.

Authors:  Gloria E Meredith; David J Rademacher
Journal:  J Parkinsons Dis       Date:  2011       Impact factor: 5.568

Review 9.  Animal models of Parkinson's disease progression.

Authors:  Gloria E Meredith; Patricia K Sonsalla; Marie-Francoise Chesselet
Journal:  Acta Neuropathol       Date:  2008-02-14       Impact factor: 17.088

10.  Stereotaxical infusion of rotenone: a reliable rodent model for Parkinson's disease.

Authors:  Nian Xiong; Jinsha Huang; Zhentao Zhang; Zhaowen Zhang; Jing Xiong; Xingyuan Liu; Min Jia; Fang Wang; Chunnuan Chen; Xuebing Cao; Zhihou Liang; Shenggang Sun; Zhicheng Lin; Tao Wang
Journal:  PLoS One       Date:  2009-11-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.